Citius Pharmaceuticals, Inc.

NasdaqCM:CTXR Stock Report

Mkt Cap: US$179.8m

We’ve recently updated our valuation analysis.

Citius Pharmaceuticals Valuation

Is CTXR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CTXR?

Other financial metrics that can be useful for relative valuation.

CTXR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-4.2x
PEG Ration/a

Price to Book Ratio vs Peers

How does CTXR's PB Ratio compare to its peers?

The above table shows the PB ratio for CTXR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2.9x
ANTX AN2 Therapeutics
1.9x40.4%US$192.9m
ASRT Assertio Holdings
1.5x15.3%US$207.2m
KMPH KemPharm
2x59.8%US$189.8m
SCPH scPharmaceuticals
6.3x60.6%US$195.5m
CTXR Citius Pharmaceuticals
1.7x57.0%US$179.8m

Price-To-Book vs Peers: CTXR is good value based on its Price-To-Book Ratio (1.7x) compared to the peer average (2.9x).


Price to Earnings Ratio vs Industry

How does CTXR's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a10.7%
n/an/an/a

Price-To-Book vs Industry: CTXR is good value based on its Price-To-Book Ratio (1.7x) compared to the US Pharmaceuticals industry average (1.8x)


Price to Book Ratio vs Fair Ratio

What is CTXR's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CTXR PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CTXR's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of CTXR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CTXR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CTXR's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CTXR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.23
US$3.60
+192.7%
11.1%US$4.00US$3.20n/a2
Jan ’24US$0.79
US$3.60
+355.7%
11.1%US$4.00US$3.20n/a2
Dec ’23US$1.23
US$3.60
+192.7%
11.1%US$4.00US$3.20n/a2
Nov ’23US$1.07
US$4.40
+311.2%
26.8%US$6.00US$3.20n/a3
Oct ’23US$1.21
US$4.40
+263.6%
26.8%US$6.00US$3.20n/a3
Sep ’23US$1.26
US$4.40
+249.2%
26.8%US$6.00US$3.20n/a3
Aug ’23US$0.90
US$4.00
+342.7%
40.8%US$6.00US$2.00n/a3
Jul ’23US$0.89
US$4.00
+347.4%
40.8%US$6.00US$2.00n/a3
Jun ’23US$0.90
US$4.00
+344.3%
40.8%US$6.00US$2.00n/a3
May ’23US$1.01
US$4.00
+296.0%
40.8%US$6.00US$2.00n/a3
Apr ’23US$1.81
US$5.00
+176.2%
20.0%US$6.00US$4.00n/a2
Mar ’23US$1.51
US$5.00
+231.1%
20.0%US$6.00US$4.00n/a2
Feb ’23US$1.52
US$5.00
+228.9%
20.0%US$6.00US$4.00n/a2
Jan ’23US$1.54
US$4.00
+159.7%
0%US$4.00US$4.00US$0.791
Dec ’22US$1.60
US$4.00
+150.0%
0%US$4.00US$4.00US$1.231
Nov ’22US$1.87
US$4.00
+113.9%
0%US$4.00US$4.00US$1.071
Oct ’22US$2.03
US$4.00
+97.0%
0%US$4.00US$4.00US$1.211
Sep ’22US$2.23
US$4.00
+79.4%
0%US$4.00US$4.00US$1.261
Aug ’22US$1.89
US$4.00
+111.6%
0%US$4.00US$4.00US$0.901
Jul ’22US$2.60
US$4.00
+53.8%
0%US$4.00US$4.00US$0.891
Jun ’22US$2.35
US$4.00
+70.2%
0%US$4.00US$4.00US$0.901
May ’22US$2.20
US$4.00
+81.8%
0%US$4.00US$4.00US$1.011
Apr ’22US$1.84
US$4.00
+117.4%
0%US$4.00US$4.00US$1.811
Mar ’22US$2.08
US$4.00
+92.3%
0%US$4.00US$4.00US$1.511
Feb ’22US$1.17
US$4.00
+241.9%
0%US$4.00US$4.00US$1.521
Jan ’22US$1.02
US$4.00
+292.2%
0%US$4.00US$4.00US$1.541

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies